Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS

References

1. 1.↵
   2. Vercellino M,
   3. Masera S,
   4. Lorenzatti M, et al

   . Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol 2009;68:489–502 doi:10.1097/NEN.0b013e3181a19a5a pmid:19525897

   CrossRefPubMed
2. 2.↵
   2. Zivadinov R,
   3. Jakimovski D,
   4. Gandhi S, et al

   . Clinical relevance of brain atrophy assessment in multiple sclerosis: implications for its use in a clinical routine. Expert Rev Neurother 2016;16:777–93 doi:10.1080/14737175.2016.1181543 pmid:27105209

   CrossRefPubMed
3. 3.↵
   2. Miller DH,
   3. Barkhof F,
   4. Frank JA, et al

   . Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125:1676–95 doi:10.1093/brain/awf177 pmid:12135961

   CrossRefPubMedWeb of Science
4. 4.↵
   2. De Stefano N,
   3. Airas L,
   4. Grigoriadis N, et al

   . Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 2014;28:147–56 doi:10.1007/s40263-014-0140-z pmid:24446248

   CrossRefPubMedWeb of Science
5. 5.↵
   2. De Stefano N,
   3. Stromillo ML,
   4. Giorgio A, et al

   . Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016;87:93–99 doi:10.1136/jnnp-2014-309903 pmid:25904813

   Abstract/FREE Full Text
6. 6.↵
   2. Schippling S,
   3. Ostwaldt AC,
   4. Suppa P, et al

   . Global and regional annual brain volume loss rates in physiological aging. J Neurol 2017;264:520–28 doi:10.1007/s00415-016-8374-y pmid:28054131

   CrossRefPubMed
7. 7.↵
   2. Zivadinov R,
   3. Havrdová E,
   4. Bergsland N, et al

   . Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology 2013;268:831–41 doi:10.1148/radiol.13122424 pmid:23613615

   CrossRefPubMed
8. 8.↵
   2. Calabrese M,
   3. Rinaldi F,
   4. Mattisi I, et al

   . The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011;77:257–63 doi:10.1212/WNL.0b013e318220abd4 pmid:21613600

   Abstract/FREE Full Text
9. 9.↵
   2. Fisher E,
   3. Lee JC,
   4. Nakamura K, et al

   . Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64:255–65 doi:10.1002/ana.21436 pmid:18661561

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Popescu V,
    3. Agosta F,
    4. Hulst HE, et al

    ; MAGNIMS Study Group. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 2013;84:1082–91 doi:10.1136/jnnp-2012-304094 pmid:23524331

    Abstract/FREE Full Text
11. 11.↵
    2. Jacobsen C,
    3. Hagemeier J,
    4. Myhr KM, et al

    . Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. J Neurol Neurosurg Psychiatry 2014;85:1109–15 doi:10.1136/jnnp-2013-306906 pmid:24554101

    Abstract/FREE Full Text
12. 12.↵
    2. Zivadinov R,
    3. Uher T,
    4. Hagemeier J, et al

    . A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Mult Scler 2016;22:1709–18 doi:10.1177/1352458516629769 pmid:26883943

    CrossRefPubMed
13. 13.↵
    2. Filippi M,
    3. Preziosa P,
    4. Copetti M, et al

    . Gray matter damage predicts the accumulation of disability 13 years later in MS. Neurology 2013;81:1759–67 doi:10.1212/01.wnl.0000435551.90824.d0 pmid:24122185

    Abstract/FREE Full Text
14. 14.↵
    2. Sormani MP,
    3. Arnold DL,
    4. De Stefano N

    . Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 2014;75:43–49 doi:10.1002/ana.24018 pmid:24006277

    CrossRefPubMed
15. 15.↵
    2. Zivadinov R,
    3. Dwyer MG,
    4. Bergsland N

    . Brain atrophy measurements should be used to guide therapy monitoring in MS: YES. Mult Scler 2016;22:1522–24 doi:10.1177/1352458516649253 pmid:27335098

    CrossRefPubMed
16. 16.↵
    2. Azevedo CJ,
    3. Pelletier D

    . Whole-brain atrophy: ready for implementation into clinical decision-making in multiple sclerosis? Curr Opin Neurol 2016;29:237–42 doi:10.1097/WCO.0000000000000322 pmid:27070219

    CrossRefPubMed
17. 17.↵
    2. Rocca MA,
    3. Battaglini M,
    4. Benedict RH, et al

    . Brain MRI atrophy quantification in MS: from methods to clinical application. Neurology 2017;88:403–13 doi:10.1212/WNL.0000000000003542 pmid:27986875

    Abstract/FREE Full Text
18. 18.↵
    2. Zivadinov R,
    3. Khan N,
    4. Medin J, et al

    . An observational study to assess brain MRI change and disease progression in multiple sclerosis clinical practice: the MS-MRIUS study. J Neuroimaging 2017;27:339–47 doi:10.1111/jon.12411 pmid:27918139

    CrossRefPubMed
19. 19.↵
    2. Kurtzke JF

    . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–52 doi:10.1212/WNL.33.11.1444 pmid:6685237

    Abstract/FREE Full Text
20. 20.↵
    2. Fetzer DT,
    3. West OC

    . The HIPAA privacy rule and protected health information: implications in research involving DICOM image databases. Acad Radiol 2008;15:390–95 doi:10.1016/j.acra.2007.11.008 pmid:18280936

    CrossRefPubMed
21. 21.↵
    2. Smith SM,
    3. Zhang Y,
    4. Jenkinson M, et al

    . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–89 doi:10.1006/nimg.2002.1040 pmid:12482100

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Vrenken H,
    3. Vos EK,
    4. van der Flier WM, et al

    . Validation of the automated method VIENA: an accurate, precise, and robust measure of ventricular enlargement. Hum Brain Mapp 2014;35:1101–10 doi:10.1002/hbm.22237 pmid:23362163

    CrossRefPubMed
23. 23.↵
    2. Dwyer MG,
    3. Silva D,
    4. Bergsland N, et al

    . Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. Neuroimage Clin 2017;15:769–79 doi:10.1016/j.nicl.2017.06.022 pmid:28706852

    CrossRefPubMed
24. 24.↵
    2. Gelineau-Morel R,
    3. Tomassini V,
    4. Jenkinson M, et al

    . The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis. Hum Brain Mapp 2012;33:2802–14 doi:10.1002/hbm.21402 pmid:21976406

    CrossRefPubMed
25. 25.↵
    2. Chu R,
    3. Tauhid S,
    4. Glanz BI, et al

    . Whole brain volume measured from 1.5T versus 3T MRI in healthy subjects and patients with multiple sclerosis. J Neuroimaging 2016;26:62–67 doi:10.1111/jon.12271 pmid:26118637

    CrossRefPubMed
26. 26.↵
    2. Lysandropoulos AP,
    3. Absil J,
    4. Metens T, et al

    . Quantifying brain volumes for multiple sclerosis patients follow-up in clinical practice: comparison of 1.5 and 3 Tesla magnetic resonance imaging. Brain Behav 2016;6:e00422 doi:10.1002/brb3.422 pmid:27110445

    CrossRefPubMed
27. 27.↵
    2. Biberacher V,
    3. Schmidt P,
    4. Keshavan A, et al

    . Intra- and interscanner variability of magnetic resonance imaging based volumetry in multiple sclerosis. Neuroimage 2016;142:188–97 doi:10.1016/j.neuroimage.2016.07.035 pmid:27431758

    CrossRefPubMed
28. 28.↵
    2. De Stefano N,
    3. Silva DG,
    4. Barnett MH

    . Effect of fingolimod on brain volume loss in patients with multiple sclerosis. CNS Drugs 2017;31:289–305 doi:10.1007/s40263-017-0415-2 pmid:28247239

    CrossRefPubMed
29. 29.↵
    2. Carmosino MJ,
    3. Brousseau KM,
    4. Arciniegas DB, et al

    . Initial evaluations for multiple sclerosis in a university multiple sclerosis center: outcomes and role of magnetic resonance imaging in referral. Arch Neurol 2005;62:585–90 doi:10.1001/archneur.62.4.585 pmid:15824257

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Traboulsee A,
    3. Simon JH,
    4. Stone L, et al

    . Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. AJNR Am J Neuroradiol 2016;37:394–401 doi:10.3174/ajnr.A4539 pmid:26564433

    Abstract/FREE Full Text
31. 31.↵
    2. Rovira À,
    3. Wattjes MP,
    4. Tintoré M, et al

    ; MAGNIMS study group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol 2015;11:471–82 doi:10.1038/nrneurol.2015.106 pmid:26149978

    CrossRefPubMed